Dr Lal PathLabs Share Price Prediction 2027: Scenario Targets, Valuation and Technical Outlook
- October 9, 2026
- Posted by: Harsh Piplani
- Category: Market
CMP Rs 1,933.60 (9 Oct 2026). 52W range Rs 1,272.60 to Rs 2,038.60. PE 58.35. 2027 base Rs 2,063, bull Rs 2,285.
Quick Answer
The Dr Lal PathLabs share price forecast for 2027 centres on a conservative case of Rs 2,002, a base case of Rs 2,063 and a bull case of Rs 2,285, against a current price of Rs 1,933.60. These targets scale today’s price by reported EPS growth at a constant PE multiple, so they rest on earnings the company has already delivered, not on broker forecasts. The base case implies 6.7% upside from today’s price. The daily technical setup reads bullish.
Dr Lal PathLabs share price prediction 2027 comes down to earnings growth and the multiple investors pay for it, and the reported numbers give a measured answer. The stock trades at Rs 1,933.60 on NSE as of 9 October 2026, 5.2% below its 52-week high of Rs 2,038.60, after the company reported net profit of Rs 509.75 crore for FY26.
This Dr Lal PathLabs stock forecast 2027 builds conservative, base and bull scenarios from exchange-reported financials, shareholding data and daily price indicators, with every assumption shown.
Click Here – Get Free Investment Predictions
Dr Lal PathLabs Share Price Today and Key Data
The Dr Lal PathLabs share price today is Rs 1,933.60 on NSE, up 1.83% on the day. The market capitalisation stands at Rs 31,877 crore. Over the past year the price has risen 25.2% from Rs 1,544.10. Every Dr Lal PathLabs stock forecast figure below starts from this price.
| Metric | Value |
|---|---|
| Company | Dr Lal PathLabs (LALPATHLAB) |
| Current Price | Rs 1,933.60 |
| 52-Week High | Rs 2,038.60 (16 September 2026) |
| 52-Week Low | Rs 1,272.60 (23 March 2026) |
| Market Cap | Rs 31,877 crore |
| PE Ratio | 58.35 |
| Industry PE | 62.79 |
| PB Ratio | 12.71 |
| EPS (TTM) | Rs 32.55 |
| Return on Equity | 20.13% |
| Debt to Equity | 0.08 |
| Dividend Yield | 1.08% |
| Book Value per Share | Rs 149.45 |
What Is the Dr Lal PathLabs Share Price Prediction for 2027?
The Dr Lal PathLabs share price prediction for 2027 is a conservative case of Rs 2,002, a base case of Rs 2,063 and a bull case of Rs 2,285. Against Rs 1,933.60, these imply 3.5% upside, 6.7% upside and 18.2% upside. They are model scenarios built from reported EPS growth, not broker targets.
| Scenario | EPS Growth Basis | EPS Estimate | PE Multiple | Implied Value | Upside vs Current Price |
|---|---|---|---|---|---|
| Conservative Case | Lower of FY26 growth (3.6%) and 4-year CAGR (9.8%) | Rs 33.71 (+3.6%) | Unchanged from today (price to EPS ratio kept constant) | Rs 2,002 | +3.5% |
| Base Case | Average of the two | Rs 34.73 (+6.7%) | Unchanged from today (price to EPS ratio kept constant) | Rs 2,063 | +6.7% |
| Bull Case | Higher of the two | Rs 35.75 (+9.8%) | Re-rated 7.6% toward industry PE of 62.79 (still at or below it) | Rs 2,285 | +18.2% |
Each target takes today’s price of Rs 1,933.60 and scales it by the EPS growth assumed for that case, which is the same as holding the PE multiple constant. The conservative case uses the lower of the FY26 EPS growth and the 4-year EPS CAGR, the base case uses their average and the bull case uses the higher figure. The bull case also re-rates the PE multiple toward the industry level, because the stock trades below it. Together they form the Dr Lal PathLabs target price range for the FY27 outlook over the next 12 months, and the range is not a point estimate.
Dr Lal PathLabs Share Price Forecast: What Has to Go Right by 2027
Each Dr Lal PathLabs target price below depends on a specific EPS outcome, and the text states that outcome next to the number.
Conservative Case for the Dr Lal PathLabs Share Price Target: Rs 2,002
Reaching Rs 2,002 needs EPS to rise 3.6% to Rs 33.71 while the stock keeps its current PE multiple. That matches the FY26 EPS growth of 3.6%.
Base Case for the Dr Lal PathLabs Share Price Target: Rs 2,063
Reaching Rs 2,063 needs EPS to rise 6.7% to Rs 34.73, the average of the FY26 growth rate and the 4-year CAGR. Net profit growth of 27.2% in Q1 FY27 is at or above that pace, which supports the target.
Bull Case for the Dr Lal PathLabs Share Price Target: Rs 2,285
Reaching Rs 2,285 needs EPS to rise 9.8% to Rs 35.75 and the PE multiple to re-rate 7.6% toward the industry PE. That is above the 52-week high of Rs 2,038.60, so it would need a fresh breakout. A daily close above the nearest resistance level of Rs 2,038.60 (52-week high) would be the first technical confirmation.
Dr Lal PathLabs Financial Performance: Revenue, Profit and Margins
Dr Lal PathLabs earned net profit of Rs 509.75 crore on revenue of Rs 2,864.18 crore in FY26, with profit up 3.6% and revenue up 12.1% compared with FY25. Diluted EPS was Rs 30.20 against Rs 29.16 a year earlier, and that earnings base anchors the Dr Lal PathLabs share price forecast. Earlier-year EPS in the table below is restated for the company’s share split or bonus issue, so every year sits on the current share count.
| Year | Revenue (Rs Cr) | Net Profit (Rs Cr) | EPS (Rs) | Operating Margin | Net Margin |
|---|---|---|---|---|---|
| FY22 | 2,139.95 | 350.29 | 20.76 | 29.38% | 16.37% |
| FY23 | 2,058.60 | 241.08 | 14.35 | 26.36% | 11.71% |
| FY24 | 2,295.81 | 362.29 | 21.46 | 30.47% | 15.78% |
| FY25 | 2,554.82 | 492.25 | 29.16 | 32.06% | 19.27% |
| FY26 | 2,864.18 | 509.75 | 30.20 | 30.90% | 17.80% |
In the latest reported quarter, Q1 FY27 (quarter ended June 2026), revenue was Rs 829.60 crore against Rs 697.90 crore a year earlier (+18.9%), and the bottom line was a net profit of Rs 170.50 crore against a net profit of Rs 134 crore (+27.2%). Operating margin was 35.03% versus 32.91% in the year-ago quarter. Cash flow from operations was Rs 635.61 crore in FY26 against Rs 568.89 crore in FY25. Together these figures set the earnings base for the Dr Lal PathLabs share price prediction.
Check the Univest Screener for live Dr Lal PathLabs fundamentals
Is Dr Lal PathLabs Overvalued or Undervalued Right Now?
Dr Lal PathLabs trades at a PE of 58.35 against an industry PE of 62.79, which places the stock at a 7.1% discount to the industry average. The price-to-book ratio is 12.71 on a book value of Rs 149.45 per share. Return on equity of 20.13% means the company earns Rs 20.13 of profit for every Rs 100 of shareholder equity.
Debt to equity is 0.08, so borrowings equal about 8% of shareholder equity. The company declared a dividend of Rs 20.50 per share for FY26, a yield of 1.08% at the current price. This valuation context frames the Dr Lal PathLabs stock price prediction for 2027 without relying on any outside forecast.
Dr Lal PathLabs Stock Analysis: Technical Outlook
Dr Lal PathLabs stock trades above its 50-day SMA of Rs 1,922.35 and above its 200-day EMA of Rs 1,693.65, and the combined daily indicators read bullish. The 52-week high of Rs 2,038.60 was set on 16 September 2026, while the 52-week low of Rs 1,272.60 came on 23 March 2026.
| Indicator | Reading | Signal |
|---|---|---|
| RSI (14) | 55.41 | Positive momentum |
| MACD (12,26,9) | 11.55 vs signal 16.55 | Bearish |
| ADX (14) | 41.80 | Established trend |
| Supertrend (10,3) | Price above Rs 1,806.23 | Bullish |
| 50-day SMA | Rs 1,922.35 | Price above |
| 200-day EMA | Rs 1,693.65 | Price above |
The nearest support level sits at Rs 1,922.35 (50-day SMA) and Rs 1,806.23 (Supertrend). The nearest resistance level sits at Rs 2,038.60 (52-week high). A sustained move above the nearest resistance would support the Dr Lal PathLabs share price prediction 2027 base case, and this Dr Lal PathLabs stock analysis uses daily candles only. Chart signals add context to the Dr Lal PathLabs share price target without changing the earnings maths.
Dr Lal PathLabs Shareholding Pattern
Promoters hold 53.19% of Dr Lal PathLabs as of Jun 2026, down from 53.79% in Jun 2025 across the last 5 quarters. FII holding is 17.36% (down from 21.68% in Jun 2025) and DII holding is 21.59% (up from 17.91% in Jun 2025), which puts combined institutional holding at 38.95%. Public shareholders own 7.86%. Shareholding data is one input for any Dr Lal PathLabs stock forecast.
Key Risks to the Dr Lal PathLabs Share Price Target for 2027
Earnings and Margin Risk
Operating margin has ranged from 26.36% to 32.06% between FY22 and FY26, so a slip toward the lower end would trim the EPS estimate behind the Dr Lal PathLabs stock forecast. Revenue was up 12.1% in FY26, and slower revenue growth would weigh on the profit path.
Size and Liquidity Risk
Market capitalisation stands at Rs 31,877 crore. Investors should check daily traded volumes and order book depth on NSE before sizing a position, because price moves can be sharper when volumes thin out. Liquidity is a practical constraint on any Dr Lal PathLabs stock price target.
Balance Sheet Risk
Debt to equity of 0.08 means borrowings stand at about 8% of shareholder equity. A rise in borrowing costs or a jump in debt would weigh on profit and on the multiple behind the Dr Lal PathLabs share price forecast.
Conclusion
This Dr Lal PathLabs stock analysis puts the share price target range for 2027 at Rs 2,002 to Rs 2,285, with a base case of Rs 2,063 against Rs 1,933.60 today. The inputs are a PE of 58.35 that sits at a 7.1% discount to the industry average, EPS growth of 3.6% in FY26 and a daily technical setup that reads bullish. The next quarterly result will show which scenario is gaining ground. This analysis is educational, so consult a SEBI-registered advisor before acting on it.
Download the Univest iOS App or Univest Android App to track Dr Lal PathLabs live price and get daily stock recommendations.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Dr Lal PathLabs Share Price Prediction 2027
What is the Dr Lal PathLabs share price target for 2027?
Ans. The Dr Lal PathLabs share price forecast for 2027 has a conservative case of Rs 2,002, a base case of Rs 2,063 and a bull case of Rs 2,285. These are model scenarios based on reported EPS growth, and they are not guaranteed outcomes.
What is the Dr Lal PathLabs share price today?
Ans. Dr Lal PathLabs trades at Rs 1,933.60 on NSE as of 9 October 2026, up 1.83% on the day. The 52-week range is Rs 1,272.60 to Rs 2,038.60.
Is Dr Lal PathLabs a good stock to buy for 2027?
Ans. The data points in different directions: the PE of 58.35 is at a 7.1% discount to the industry average, EPS grew 3.6% in FY26 and the daily technical setup reads bullish. This article does not constitute investment advice, so consult a SEBI-registered advisor before deciding.
Can Dr Lal PathLabs stock reach Rs 2,285 in 2027?
Ans. Reaching Rs 2,285 needs EPS to rise 9.8% from Rs 32.55 and the PE multiple to re-rate toward the industry PE of 62.79, plus a daily close above Rs 2,038.60 (52-week high). This is a scenario, not a guarantee.
What are the support and resistance levels for Dr Lal PathLabs?
Ans. The nearest support levels are Rs 1,922.35 (50-day SMA) and Rs 1,806.23 (Supertrend), and the nearest resistance levels are Rs 2,038.60 (52-week high).
What are the main risks for Dr Lal PathLabs stock in 2027?
Ans. The main risks to the Dr Lal PathLabs share price forecast are a fall in operating margin from the 26.36% to 32.06% range seen since FY22, slower revenue growth after FY26 revenue was up 12.1%, and thin trading volumes. Debt to equity of 0.08 adds balance sheet sensitivity.
How is the Dr Lal PathLabs target price for 2027 calculated?
Ans. Each target scales the current price by assumed EPS growth at a constant PE multiple. The conservative case uses 3.6% growth, the base case 6.7% and the bull case 9.8%, all drawn from the company’s reported FY26 and 4-year EPS growth.
